Evgen Pharma Share Discussion Threads

[wins73] 08/3/2018 13:05

Why does this keep falling?

[parob] 07/3/2018 12:24

Joined you guys with an initial 45700. Market cap seems way too cheap at £12 million. This could do an N4P once momentum builds.

[saw89] 02/3/2018 12:13

IPO was nearly 40p and broker target is nearly 100p

So there's plenty of headroom here and barely off the ground from it's lowest lows.

looking at the chart when it gets going it really moves.

[rathean] 02/3/2018 10:38

More sustained buying, could see 20p again before the results.

[pdt] 01/3/2018 17:00

From the interim results they said;

"Early stage pipeline - In collaboration with the medicinal chemists at the University of Seville we have created a range of novel compounds based upon the sulforaphane core structure. Evgen has in-licensed the Seville intellectual property presenting us with multiple new chemical entities based upon sulforaphane. Screening of a series of such novel, proprietary, sulforaphane analogues is underway at the University of Liverpool and the full dataset will be evaluated during Q1 of calendar year 2018."

I see the Uni of Seville have just released some research which may be relevant to this;

"NMR study on the stabilization and chiral discrimination of sulforaphane enantiomers and analogues by cyclodextrins"



Hopefully a step forward in the science.

[pdt] 01/3/2018 10:20

Yes, there is certainly a pick up in the volume of trades.

The Capital Network report above suggested that the interim cancer trial readout may be the trigger for licencing activity before the full results at the end of the year.

I think there is growing interest in targeting cancer stem cells. The recent University of Manchester poster on SFX-01 at the Breast Cancer Conference was positive and I see Stephen Franklin was interviewed in a recent Cancer Stem Cell report.

Interesting times :)

[moneytree1] 01/3/2018 10:10

Q1 screening of cancer cells utilising the Sulforadex technology full data readout due in next 4 weeks see page 3 of report, H1 breast cancer interim phase 2 trial readout

positioning ahead of news...could get interesting.gl

[rathean] 01/3/2018 09:00

Nice volume this morning, leaky broker ahead of rns wouldn't surprise me.

[lambo222] 30/1/2018 11:19

I think it will slip below the 12p placing price as the placing shares are flipped for a nice profit especially with full trial readout not for another 11 months

[rathean] 30/1/2018 09:30

Slipping back to floor support levels, good price to buy in ahead of next RNS.

[pdt] 15/1/2018 13:09

The Breast Cancer conference has a PDF available on it's website. The poster information is on page 80



On the same page is a study by AstraZeneca doing a similar study with Progesterone receptor antagonists to inhibit cancer stem cell activity. I would be interested to know how they compare.

[pdt] 15/1/2018 07:39

More scientific evidence released today by the company supporting their Breast cancer treatment. I think the Hardman report estimated the market for this treatment at $5 billion per annum. Look forward to the interim phase II read out by June this year. Early signs are that it works and increasingly they are providing the science of why it works. Hugely important to breast cancer patients.

[pdt] 12/1/2018 20:29

Another study showing the effectiveness against cancer stem cells;

"Sulforaphane reverses gefitinib tolerance in human lung cancer cells via modulation of sonic hedgehog signaling"



Gefitinib is marketed by Astrazeneca under the trade name Iressa. Currently doing $500m per annum in sales.

[rathean] 12/1/2018 11:41

Chart suggests we're just off the bottom. Any positive news will see it 25p again.

[dave444] 05/1/2018 20:35

3.4m shares still need to be declared

[dave444] 04/1/2018 09:31

Surprised that no holding statements have been declared after fundraising

[rathean] 13/12/2017 10:16

Agreed #Tilly99, share price discounts huge upside. Great entry point, it'll rise quickly when it goes

[tilly99] 13/12/2017 08:50

Floated at 37p? And only had good news since

[tilly99] 13/12/2017 08:35

Dave Doubt it!!All time low and great collaborations !

[pdt] 13/12/2017 07:33

Great news about Kings and Stroke.

Here is some published information on their work with sulforaphane and stroke

[dave444] 12/12/2017 20:51

Could also be 12p!

[tilly99] 11/12/2017 11:06

Great piece from EvgDave you could be right!! 100p wow

[supernumerary] 11/12/2017 11:01

Just goes to show there are no slam dunks in the biotech business. The researchers in this COPD trial sound utterly bewildered by the result, but all credit to them for publishing...